In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery

In this work we present the development of in situ gelling nanosuspension as advanced form for fluticasone propionate nasal delivery. Drug nanocrystals were prepared by wet milling technique. Incorporation of drug nanocrystals into polymeric in situ gelling system with pectin and sodium hyaluronate as constitutive polymers was fine-tuned attaining appropriate formulation surface tension, viscosity and gelling ability. Drug nanonisation improved the release profile and enhanced formulation mucoadhesive properties. QbD approach combining formulation and administration parameters resulted in optimised nasal deposition profile, with 51.8% of the dose deposited in the middle meatus, the critical region in the treatment of rhinosinusitis and nasal polyposis. Results obtained in biocompatibility and physico-chemical stability studies confirmed the leading formulation potential for safe and efficient nasal corticosteroid delivery.

Automated summary

This study presents the development of an in situ gelling nanosuspension as an advanced form for delivering fluticasone propionate to the nasal cavity. Drug nanocrystals were prepared using a wet milling technique and incorporated into a polymeric in situ gelling system. The drug nanonization improved release profile and mucoadhesive properties. By optimizing formulation and administration parameters, the nasal deposition profile was optimized, with a significant portion of the dose deposited in the critical region for treating rhinosinusitis and nasal polyposis.